What is Romark?
Founded in 1993 and headquartered in Tampa, Florida, Romark Laboratories has dedicated itself to addressing unmet medical needs in infectious diseases and oncology. The company's core strategy revolves around the identification and progression of novel small molecule therapeutics. Romark's commitment to innovation positions it within a highly competitive yet vital sector of the pharmaceutical industry, aiming to bring impactful treatments to patients worldwide.
How much funding has Romark raised?
Romark has raised a total of $73.2M across 7 funding rounds:
Private Equity
$23.1M
Private Equity
$9.6M
Private Equity
$15M
Private Equity
$10.8M
Debt
$10.7M
Debt
$2M
Debt
$2M
Private Equity (2009): $23.1M, investors not publicly disclosed
Private Equity (2010): $9.6M, investors not publicly disclosed
Private Equity (2013): $15M, investors not publicly disclosed
Private Equity (2014): $10.8M featuring Source Capital Group, Inc., International Assets Advisory, LLC, and Williams Financial Group
Debt (2015): $10.7M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Debt (2021): $2M led by PPP
Key Investors in Romark
Source Capital Group, Inc.
Source Capital Group, Inc. is an investment banking firm specializing in small to medium-sized transactions, with expertise in various financial services including securities, investment management, and business lending.
International Assets Advisory, LLC
International Assets Advisory, LLC is an independent broker-dealer that has been providing services to financial professionals and institutions since 1982.
Williams Financial Group
Williams Financial Group is a financial services firm offering securities, brokerage, advisory, and investment services to independent Financial Professionals, primarily serving individual investors and select institutions.
What's next for Romark?
With a history of securing significant enterprise-level funding and recent strategic investments, Romark appears poised for accelerated growth and development. The company's focus on small molecules for challenging diseases suggests a long-term vision for clinical advancement and potential commercialization. Future endeavors will likely involve further R&D investment, clinical trial progression, and strategic partnerships to maximize the therapeutic potential of its pipeline. The sustained capital infusion indicates confidence from investors in Romark's scientific approach and market strategy.
See full Romark company page
